Abstract:Dopamine receptors are therapeutic targets for the treatment of various neurological and psychiatric disorders, including Parkinson's and Alzheimer's. Previously, PF-06649751 (tavapadon), PF-2562 and PW0464 have been discovered as potent and selective G protein-biased D1/D5 receptor agonists with optimal pharmacokinetic properties. However, no selective D5R agonist has been reported yet. In this context, we designed and synthesized forty non-catecholamines-based pyrimidine derivatives and identified four pyrimidine derivatives as selective D5R partial agonists. Using cAMP-based GloSensor assay in transiently transfected HEK293T cells with human D1 or D5 receptors, we discovered that compound 5c (4-(4-bromophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine) exhibited modest D5R agonist activity. This leads us to explore various modifications of this scaffold to improve the D5 agonist potency and efficacy. Using molecular docking, and rational design followed by their evaluation at D1 and D5 receptors for agonist activity, we identified three new derivatives, 5j, 5h, and 5e. The most potent compound of this series 5j (4-(4-iodophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine), exhibited EC50 of 269.7 ± 6.6 nM. Mice microsomal stability studies revealed that 5j is quite stable (>70 % at 1 hr). Furthermore, pharmacokinetic analysis of 5j (20 mg/kg, p.o) in C57BL/6j mice showed that 5j is readily absorbed via oral route of dosing and also enters into the brain (plasma Tmax: 1 h, Cmax: 51.10 ± 13.51 ng/ml; Brain Tmax: 0.5 h, Cmax: 22.54 ± 4.08 ng/ml). We further determined the in-vivo effect of 5j on cognition in scopolamine-induced amnesia in C57BL/6j mice. We observed that 5j (10 mg/kg, p.o) alleviated scopolamine-induced impairment in short-term memory and social recognition, which were blocked by D1/D5 antagonist SCH23390 (0.1 mg/kg, i.p.). Furthermore, 5j did not exhibit any cytotoxicity (up to 10 µM) or in vivo acute toxicity up to 200 mg/kg (p.o). These results strongly suggest that 5j could be further developed for treating neurological disorders wherein the D5 receptors play pivotal roles.

Synthesis and Structure–activity Relationships of 5-Substituted Pyridine Analogues of 3-[2-((s)-pyrrolidinyl)methoxy]pyridine, A-84543: A Potent Nicotinic Receptor Ligand

Synthesis And Structure-Activity Relationships Of Pyridine-Modified Analogs Of 3-[2-((S)-Pyrrolidinyl)Methoxy]Pyridine, A-84543, A Potent Nicotinic Acetylcholine Receptor Agonist

Novel Pyridyl Ring C5 Substituted Analogues Of 3-(1-Methyl-2(S)- Pyrrolidinylmethoxy)Pyridine (A-84543) As Highly Selective Agents For Neuronal Nicotinic Acetylcholine Receptor(Nachr)

Structure–Activity Studies of Diazabicyclo[3.3.0]octane-Substituted Pyrazines and Pyridines As Potent Α4β2 Nicotinic Acetylcholine Receptor Ligands

Biososteric Replacement in the Design and Synthesis of Ligands for Nicotinic Acetylcholine Receptors

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles As Bioisosteric Replacements for the Pyridine Ring in Nicotine

QSAR Study of a Large Set of 3-Pyridyl Ethers As Ligands of the Α4β2 Nicotinic Acetylcholine Receptor

Design of novel 3,6-diazabicyclo[3.1.1]heptane derivatives with potent and selective affinities for α4β2 neuronal nicotinic acetylcholine receptors

QSAR Studies of Novel Pyridylamine Ligands for the Nicotinic Acetylcholine Receptor

Synthesis and Structure−Activity Relationships of Trisubstituted Phenyl Urea Derivatives As Neuropeptide Y5 Receptor Antagonists

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

[ 125/123 I] 5-Iodo-3-pyridyl Ethers

Design and Synthesis of New Agents for Neuronal Nicotinic Acetylcholine Receptor (nachrs) Imaging.

The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs

Synthesis and Nicotinic Acetylcholine Receptor Binding Affinities of 2- and 3-Isoxazolyl-8-azabicyclo[3.2.1]octanes.

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.

Discovery of Fused Heterocyclic Carboxamide Derivatives As Novel Α7-Nachr Agonists: Synthesis, Preliminary SAR and Biological Evaluation.

Discovery, Cocrystallization and Biological Evaluation of Novel Piperidine Derivatives As High Affinity Ls-AChBP Ligands Possessing Α7 Nachr Activities.

Discovery and structure - activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists

Synthesis and biological activity of 1H-pyrrol-2(5H)-ones